Core Viewpoint - NervGen Pharma Corp. is amending the exercise price of its 2022 Warrants from US$1.75 to the Canadian equivalent of C$2.44 to align with its functional currency and simplify accounting treatment, while all other terms remain unchanged [1] Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury and other neurological disorders [1][3] - The company is evaluating its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study for spinal cord injury [3] Product Information - NVG-291 is a first- and potential best-in-class therapeutic peptide that enables the nervous system to repair itself, with exclusive worldwide rights held by NervGen [2] - The technology for NVG-291 is licensed from Case Western Reserve University, based on studies showing its preclinical efficacy in promoting neurorepair and functional improvement in spinal cord injury models [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Designation from the EMA for spinal cord injury [2]

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to ShareholdersAugust 26, 2025 7:30 AM EDT | Source: NervGen Pharma Corp.Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gainsOngoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory di ...

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury August 21, 2025 7:30 AM EDT | Source: NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurologic disorders, toda ...